Related Experiment Videos
Retroviral integrase inhibitors year 2000: update and perspectives
Y Pommier1, C Marchand, N Neamati
1Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, Bethesda, MD 20892-4255, USA. pommier@nih.gov
Antiviral Research
|September 7, 2000
Abstract:
HIV-1 integrase is an essential enzyme for retroviral replication and a rational target for the design of anti-AIDS drugs. A number of inhibitors have been reported in the past 8 years. This review focuses on the recent developments in the past 2 years. There are now several inhibitors with known sites of actions and antiviral activity. The challenge is to convert these leads into drugs that will selectively target integrase in vivo, and can be added to our antiviral armamentarium.